Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RC148 + docetaxel
- Development stage
- Unknown
- Lead developer
- RemeGen
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
RC148 + docetaxel is a combination therapy under clinical investigation for the treatment of various solid tumors, including non-small cell lung cancer and breast cancer. RC148 is a bispecific antibody developed by RemeGen that targets both programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF), acting as an immunomodulator and antiangiogenic agent. Docetaxel is a well-established taxane-class chemotherapeutic agent that inhibits microtubule depolymerization, thereby disrupting mitosis and inducing apoptosis in rapidly dividing cells. The combination aims to leverage immune checkpoint inhibition with cytotoxic chemotherapy to enhance antitumor efficacy[3][6][8].
- Other names
- none
02
Targets
TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on RC148 + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RC148 + docetaxel.